ASH 65th Annual Meeting & Exposition: Friday Satellite Symposia

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

This program is supported by GlycoMimetics, Inc., Rigel Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Gilead Sciences, Inc., Daiichi Sankyo, Inc., and Curis, Inc.

11:00 a.m. - 2:00 p.m. Pacific time

San Diego Convention Center
Room 6A

Access Program Details

The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together 5 clinical experts to highlight novel agents in the management of AML, including the latest clinical data and application of targeted therapies, combination, maintenance therapy, and beyond.


Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, TX


Courtney D. DiNardo, MD, MSc
The University of Texas MD Anderson Cancer Center
Houston, TX

Amir T. Fathi, MD
Massachusetts General Hospital
Boston, MA

Gail J. Roboz, MD
Weill Cornell Medicine and The New York Presbyterian Hospital
New York, NY

Eytan M. Stein
Memorial Sloan Kettering Cancer Center
New York, NY

Kelly Donald , Physicians' Education Resource, LLC